Cardinal Health 200 LLC
$209.6K 78 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Neocis Inc.
Neocis Inc. reported $209,571.71 across General Payments, Research, and Ownership to 76 physicians and teaching hospitals across 76 transactions.
- $209.6K Below-median payer
- All-tracks total
- 76 Below-median volume
- Transactions
- 76 Below-median reach
- Recipients
- +$67.5K
- General Payments vs PY2023
Neocis Inc. reported $209,571.71 across all CMS Open Payments tracks (General + Research + Ownership) to 76 physicians and teaching hospitals in Program Year 2024 - ranking #986 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $209,571.71, averaging $2.8K per recipient.
Neocis Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer neocis-inc Neocis Inc.
$209.6K · #986/1,925 · 0.0% industry · PY2024
- TOT $209.6K
- RANK #986
- SHARE 0.0%
- TXN 76
- RCP 76
- CAT 3
- GEN $209.6K
- ΔGEN +$67.5K
- TOP1 21.3%
- PY 2024
Volume peers
Nearest volume peer: Cardinal Health 200 LLC ($209.6K)
Neocis Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Neocis Inc.'s CMS-reported General Payments increased by $67.5K (+47.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NEOCIS INC.PY2023: NEOCIS INC.PY2024: Neocis Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $142,084.75
- PY2024
- $209,571.71
What the Data Shows for Neocis Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Neocis Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $205.0K across 73 transactions, 97.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Neocis Inc. made 3 types of general payments. "Consulting Fee" is the largest category at $205.0K, 97.8% of General Payments.
How Neocis Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $205.0K | 73 | 97.8% |
| Compensation for Services Other Than Consulting | $4.0K | 1 | 1.9% |
| Food and Beverage | $537.95 | 2 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $130,127.62 (62.1%) of $209,571.71 in this company's General Payments records across 24 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Neocis Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Leo Haydt
$44,604.67 across 7 reported transactions
- 2
Scott Ewing
$30,542.71 across 5 reported transactions
- 3
Jeremy Thompson
$20,313.87 across 19 reported transactions
- 4
Sathish Gobichettypalayam
$20,266.37 across 6 reported transactions
- 5
Hanife Bayraktaroglu
$14,400.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Neocis Inc.'s spend rank (#986 of 1,925, bottom 49% by spend) and concentration rank (#1,011 of 1,838, bottom 45% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Mesh Suture Inc : $11.2K total payments, HHI 1063
- Akebia Therapeutics Inc : $497.0K total payments, HHI 1056
- Omnia Medical, LLC : $2.0M total payments, HHI 1054
- Afaxys, Inc. : $17.3K total payments, HHI 1054
- ARKRAY USA, Inc. : $174.72 total payments, HHI 1052
- TransMedics, Inc. : $1.2M total payments, HHI 1045
- Neocis Inc. (this company) : $209.6K total payments, HHI 1044
- MML US, Inc. : $954.7K total payments, HHI 1043
- Hoffmann-La Roche Limited : $185.6K total payments, HHI 1042
- NeuroLogica Corporation, a subsidiary of Samsung Electronics Co., Ltd. : $273.1K total payments, HHI 1042
- PolyMedics Innovations Inc. : $62.1K total payments, HHI 1036
- Qiagen, LLC : $659.8K total payments, HHI 1034
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Neocis Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Neocis Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Neocis Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Mindray DS USA, Inc.
$209.1K 1,528 recipients
Compare payment profiles
Surgical Specialties Corporation (us), Inc. (dba Corza Medical)
$210.1K 577 recipients
Compare payment profiles
Diagnostica Stago, Inc
$208.5K 22 recipients
Compare payment profiles
Synapse Biomedical Inc
$207.4K 19 recipients
Compare payment profiles
Mohawk Hospital Equipment, Inc.
$212.0K 4 recipients
Compare payment profiles
Put this to use
Neocis Inc. ranks #986 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Neocis Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.